This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Buy These 5 Hated Stocks to Beat the S&P

Becton Dickinson

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Chances are you've bought a product from Becton Dickinson (BDX - Get Report) before. You just might not know it.

Becton is one of the biggest medical device firms in the world, with a huge business stocking hospitals and doctors' offices with scalpels, syringes, and surgical instruments. That means that you may have paid for a Becton syringe for your last flu shot without realizing it. Becton Dickinson also makes complex high-margin medical equipment, including oncology and pathology diagnostic devices. The medical device business is lucrative, but its bread and butter is still the boring medical product unit.

Exposure to boring health care spending is actually a big benefit. While there's considerable competition in the medical device space, there's a lot less in Becton's main line. Only a couple of firms can compete with Becton's scale, technology and cost at that level.

Regardless of where you sit on the political spectrum, Obamacare is a big catalyst for firms like BDX. With more Americans getting access to healthcare, medical consumable volume is ensured strong growth.

Financially, Becton Dickinson is in solid shape with consistent double digit net profit margins and cash coverage that offsets around half of the firm's total debt. A 2.3% dividend yield rounds out the picture for this company.

Short sellers are active in BDX, spiking the firm's shares 10.8. That's a high enough level to warrant a short squeeze in the first quarter of 2013.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
CERN $56.96 0.00%
BDX $160.90 0.00%
CRM $77.25 0.00%
PXD $165.61 0.00%
SWK $112.08 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs